745 Route 202-206, Suite 303
Bridgewater, NJ 08807
Phone: 908-517-9500
Fax: 908-429-4307

www.cormedix.com

Disclaimer

CorMedix (AMEX:CRMD)

 

 

8/24/10 - Griffin Securities Report

8/4/10 - Crystal Research Report

7/15/10 - Research Report (PDF): National Securities Issues "Buy" Recommendation

CorMedix's Blog and Email List
Access Pharma Blog Subscribe to ProActive Onsite Box

CorMedix Inc. (AMEX:CRMD) is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney (cardiorenal) disease.

Cardiorenal disease includes a broad range of inter-related cardiovascular, kidney and metabolic problems which share the common trait of underlying oxidative stress and blood vessel malfunction (endothelial dysfunction). 

June 3, 2010 - Maxim Group initiates resarch coverage with $5.00 price target. 

 

PIPELINE DEVELOPMENTS/COMPOUNDS

CARDIORENAL DISEASE

New Frontiers in Medicine
The field of cardiorenal disease encompasses a broad range of interrelated cardiovascular, kidney and metabolic problems. A cardiorenal disease involves dysfunction of both the kidney and cardiovascular systems. From a strict scientific point of view, it is now recognized that cardiovascular and kidney diseases are inseparable. In fact oxidative stress and malfunction of blood-vessel lining (endothelial dysfunction) are common to both. This finding could help millions of sufferers worldwide.

What is CKD?
Chronic kidney disease (CKD) is characterized by loss of kidney function, evidenced by an elevated serum creatinine level and/or increased protein loss in the urine. It is largely undetected but truly epidemic in scope. There are an estimated 20 million U.S. adults with CKD and 20 million more at risk. Furthermore, it's a silent killer because most patients with CKD don't know they have it and they are more likely to die from accelerated cardiovascular disease than to go on to dialysis.

Cardiorenal diseases arise from an imbalance in the body. Like cardiovascular diseases, the most common causes of CKD include hypertension and diabetes.

We believe that excess labile (free) iron plays a causative role in acute kidney injury and the progression of CKD. Our therapeutic goals will be to prevent/reduce acute kidney injury and delay or prevent progression of CKD.

What is ‘End-Stage' CKD?
CKD patients with insufficient remaining kidney function are said to have end-stage renal disease. These patients need some form of chronic dialysis. In the U.S., more than 90 percent of patients requiring chronic dialysis receive hemodialysis (HD) - a procedure that requires vascular access allowing for a high rate of blood flow through a dialysis machine three times a week.

Patients undergoing hemodialysis require access to the vascular system in order to perform treatments on a multiple scheduled basis each week. According to a U.S. Renal Data System 2008 Annual Data Report, approximately 80,000 hemodialysis patients relied on a central venous catheter (CVC) in 2008.

There is a significant unmet need for prevention of catheter-related blood stream infections in the hemodialysis patient population.

CRMD @ Wikinvest

CRMD Yahoo Finance News Feed

Friday, Sep 3, 2010
[Business Wire] - BRIDGEWATER, N.J.----CorMedix Inc. , a pharmaceutical company...Read More
Sunday, Aug 29, 2010
Thursday, Aug 12, 2010
Thursday, Aug 12, 2010
[Business Wire] - BRIDGEWATER, N.J.----CorMedix Inc. , a pharmaceutical company...Read More
Thursday, Aug 12, 2010
Tuesday, Aug 10, 2010
[Business Wire] - BRIDGEWATER, N.J.----CorMedix Inc. , a pharmaceutical company...Read More
Tuesday, Aug 3, 2010
[Business Wire] - BRIDGEWATER, N.J.----In view of the unusual market activity...Read More
Wednesday, Jun 30, 2010